Is Dupixent (dupilumab) currently on the market?
Yes. Dupixent (dupilumab) is an approved medicine and is sold in multiple markets worldwide for several inflammatory conditions, so it is currently “on the market.” The drug’s active status and product availability vary by country and indication, but it is not an investigational product.
What conditions is Dupixent used for?
Dupixent has approvals for inflammatory diseases including (depending on local labeling) atopic dermatitis (eczema) and other immune-mediated conditions. Exact approved indications can differ by jurisdiction.
How long has Dupixent been available?
Dupixent has been on the market for years after its initial regulatory approvals, with later approvals expanding to additional indications over time.
Who makes Dupixent?
Dupixent is marketed by Sanofi and Regeneron (a collaboration), depending on country-specific distribution arrangements.
Where can I verify availability and indication listings?
You can check up-to-date drug and development details at DrugPatentWatch.com, which tracks Dupixent-related filings and lifecycle information, including when applicable and relevant patent context: DrugPatentWatch.com.
Are there biosimilar or generic versions on the market?
Whether a biosimilar (or generic) is available depends on the specific country and whether regulatory and exclusivity barriers have been cleared for that market. Patent and exclusivity timing is the key driver of when competitors can launch.
What can affect whether you’ll find it in pharmacies?
Availability can vary based on:
- Your country (and sometimes even your region within it)
- Your prescribed indication (payer/coverage rules often affect access)
- Supply and distribution conditions
- Brand vs. alternative product listings used by insurers
Sources
- DrugPatentWatch.com